South San Francisco, CA, United States of America

Sandip Panicker

This inventor holds 24 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Antibody Therapeutics. Top assignees: True North Therapeutics, Inc., Bioverativ USA Inc., Vega Therapeutics, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sandip Panicker. Retrieved from https://idiyas.com/inventor/sandip-panicker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 3 (Patent Applications = 18)

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 120(Granted Patents)

Company Filing History:

9 out of 9

True North Therapeutics, Inc.

Vega Therapeutics, Inc.

Electra Therapeutics, Inc.

patent

6. 1 out of 1

Star Therapeutics, Inc.

patent

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Anti-Complement Factor Bb

SIRP Antibodies

Protein S Antibodies

Anti-C1s Antibodies

Complement Activity

Polynucleotides

Humanized Antibodies

Complement Activation

Therapeutic Uses

Antibody Production

Immunology

Biotechnology

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715910 - ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF (2026-08-25),

2. 12503508 - SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOF (2025-12-23),

3. 12441810 - Protein S antibodies, methods of making and uses thereof (2025-10-14),

4. 12421320 - Protein S antibodies, methods of making and uses thereof (2025-09-23),

5. 12391750 - Anti-C1S antibodies and methods of use thereof (2025-08-19),

6. 12240917 - Anti-complement C1s antibodies and uses thereof (2025-03-04),

7. 12215169 - Anti-complement C1s antibodies and uses thereof (2025-02-04),

8. 12187797 - SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof (2025-01-07),

9. 12145999 - Protein S antibodies, methods of making and uses thereof (2024-11-19),

10. 11851482 - Anti-complement factor Bb antibodies and uses thereof (2023-12-26),

11. 11246926 - Polynucleotides encoding anti-C1s antibodies (2022-02-15),

12. 11192944 - Methods of inducing complement activity (2021-12-07),

13. 10934347 - Anti-complement factor BB antibodies and uses thereof (2021-03-02),

14. 10729767 - Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage (2020-08-04),

15. 10457745 - Anti-complement C1s antibodies (2019-10-29),

Title: Sandip Panicker: Innovator in Complement C1s Antibody Research

Introduction

Sandip Panicker is a notable inventor based in South San Francisco, California, known for his significant contributions to the field of biotechnology. With an impressive repertoire of 19 patents, he has been a driving force in the development of innovative antibody therapies.

Latest Patents

His latest notable patents focus on anti-complement C1s antibodies and their uses. The present disclosures detail antibodies that bind to the complement C1s protein, alongside nucleic acid molecules that encode these antibodies. Some embodiments illustrate how these anti-complement C1s antibodies can inhibit the proteolytic activity of C1s. Furthermore, the disclosures provide compositions containing these antibodies, as well as methods for their production and use.

Career Highlights

Throughout his career, Sandip has worked with prominent biotech companies, notably True North Therapeutics, Inc. and Bioverativ USA Inc. His work at these organizations has contributed to advancements in therapeutic solutions derived from antibody research.

Collaborations

Collaborating with esteemed colleagues such as Graham Parry and Peter Van Vlasselaer, Sandip Panicker has been part of a dynamic network of innovators and researchers, enhancing the knowledge base and practical applications in his field.

Conclusion

In summary, Sandip Panicker showcases a vibrant career marked by innovation in the development of anti-complement C1s antibodies. His ongoing contributions continue to influence biotechnology, emphasizing the importance of his research in creating novel therapeutic options.

Profile summary based on public USPTO records.